fda compounding semaglutide news october 2025 shortage ends as sets deadline for compounders September 2, 2025: U.S. compounding

Why Choose Intra-V

The Novel Long Acting GLP-1/Glucagon Dual Agonist HM12525A Reduces Body Weight and Improves Glycermic Control in Rodent Models

Choose Your Reconstitution Format Math is different for retatrutide vs CJC/Ipa, and different again for separate CJC and Ipa vials vs the pre-blended combo

In atherosclerosis, most therapeutic approaches aim to control hypertension and hyperlipidemia or modulate hemostasis in order to avoid thrombotic complications (Weber and Noels, 2011)

Retatrutide is an investigational GLP-1/GIP/glucagon triple agonist with no MHRA, EMA, or FDA marketing authorisation

Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes